secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001453687-26-000051
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated
--------------------------------------------------------------------------------

- Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.
- FDA accepted IND for Descartes-08 in myositis; seamless adaptive Phase 2 TRITON trial expected to start 1H26.
- Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis initiated.
- Two Nature Medicine publications; Phase 2b MG data showed 55% median prednisone dose reduction at Month 12, no CRS or ICANS.
- Cash resources expected to fund operations including Phase 3 trial completion through mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/0001453687-26-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/rnac-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001453687-26-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer